Individual and Specified Hormones - Medical Devices Pipeline Assessment, 2019

Published : Nov-2019

No. of Pages : 88

order by fax Inquire before Buying request discount

Table of Contents
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Individual and Specified Hormones Overview 7
3 Products under Development 8
3.1 Individual and Specified Hormones - Pipeline Products by Stage of Development 8
3.2 Individual and Specified Hormones - Pipeline Products by Segment 9
3.3 Individual and Specified Hormones - Pipeline Products by Territory 10
3.4 Individual and Specified Hormones - Pipeline Products by Regulatory Path 11
3.5 Individual and Specified Hormones - Pipeline Products by Estimated Approval Date 12
4 Individual and Specified Hormones - Pipeline Products under Development by Companies 13
4.1 Individual and Specified Hormones Companies - Pipeline Products by Stage of Development 13
4.2 Individual and Specified Hormones - Pipeline Products by Stage of Development 14
5 Individual and Specified Hormones Companies and Product Overview 16
5.1 Alere Inc Company Overview 16
5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 16
5.2 AMS Diagnostics LLC Company Overview 17
5.2.1 AMS Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 17
5.3 Beckman Coulter Inc Company Overview 19
5.3.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 19
5.4 Carolina Liquid Chemistries Corp Company Overview 20
5.4.1 Carolina Liquid Chemistries Corp Pipeline Products & Ongoing Clinical Trials Overview 20
5.5 Ceres Nanosciences Inc Company Overview 22
5.5.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 22
5.6 Columbia University Company Overview 23
5.6.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 23
5.7 DIANA Biotechnologies Company Overview 24
5.7.1 DIANA Biotechnologies Pipeline Products & Ongoing Clinical Trials Overview 24
5.8 DiaSorin SpA Company Overview 25
5.8.1 DiaSorin SpA Pipeline Products & Ongoing Clinical Trials Overview 25
5.9 Immunodiagnostic Systems Holdings plc Company Overview 28
5.9.1 Immunodiagnostic Systems Holdings plc Pipeline Products & Ongoing Clinical Trials Overview 28
5.10 Novartis AG Company Overview 30
5.10.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 30
5.11 OJ-Bio Ltd (Inactive) Company Overview 31
5.11.1 OJ-Bio Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31
5.12 Roche Diagnostics International Ltd Company Overview 32
5.12.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 32
5.13 Sendera Discovery Company Overview 37
5.13.1 Sendera Discovery Pipeline Products & Ongoing Clinical Trials Overview 37
5.14 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 38
5.14.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
5.15 Siemens Healthcare Diagnostics Inc Company Overview 44
5.15.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.16 Siemens Healthineers AG Company Overview 51
5.16.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 51
5.17 Tosoh Bioscience Inc Company Overview 52
5.17.1 Tosoh Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 52
6 Individual and Specified Hormones- Recent Developments 53
6.1 Nov 04, 2019: Luminex reports third quarter 2019 results and submission of VERIGENE II Gastrointestinal Flex Assay to the FDA 53
6.2 Oct 16, 2019: Abbott reports third-quarter 2019 results 53
6.3 Oct 01, 2019: Fortress Diagnostics announces £8m investment in new headquarters 56
6.4 Sep 12, 2019: Repositioning of Biocrates: Management change and new round of financing 57
6.5 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 57
6.6 Jul 31, 2019: Luminex reports second quarter 2019 financial results and increase in quarterly dividend 58
6.7 Jul 29, 2019: Siemens Healthineers continues to drive growth forward 59
6.8 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers 60
6.9 Jul 17, 2019: Abbott reports second-quarter 2019 results 61
6.10 Jun 19, 2019: Immunodiagnostic Systems Holdings: Final results for year ended 31 March 2019 63
7 Appendix 85
7.1 Methodology 85
7.2 About GlobalData 88
7.3 Contact Us 88
7.4 Disclaimer 88

List of Tables
Table 1: Individual and Specified Hormones - Pipeline Products by Stage of Development 9
Table 2: Individual and Specified Hormones - Pipeline Products by Segment 10
Table 3: Individual and Specified Hormones - Pipeline Products by Territory 11
Table 4: Individual and Specified Hormones - Pipeline Products by Regulatory Path 12
Table 5: Individual and Specified Hormones - Pipeline Products by Estimated Approval Date 13
Table 6: Individual and Specified Hormones Companies - Pipeline Products by Stage of Development 14
Table 7: Individual and Specified Hormones - Pipeline Products by Stage of Development 15
Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 18
Table 9: Vitamin D Assay - Product Status 18
Table 10: Vitamin D Assay - Product Description 18
Table 11: AMS Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 19
Table 12: LIASYS 330 - Vitamin D Assay - Product Status 19
Table 13: LIASYS 330 - Vitamin D Assay - Product Description 19
Table 14: Liasys 450 - Vitamin D Assay - Product Status 19
Table 15: Liasys 450 - Vitamin D Assay - Product Description 20
Table 16: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 21
Table 17: UniCel DxI 860i Synchron Access Clinical System - Vitamin D Assay - Product Status 21
Table 18: UniCel DxI 860i Synchron Access Clinical System - Vitamin D Assay - Product Description 21
Table 19: Carolina Liquid Chemistries Corp Pipeline Products & Ongoing Clinical Trials Overview 22
Table 20: CLC 480 Analyzer - Vitamin D Assay - Product Status 22
Table 21: CLC 480 Analyzer - Vitamin D Assay - Product Description 22
Table 22: CLC 720i Analyzer - Vitamin D Assay - Product Status 24
Table 23: CLC 720i Analyzer - Vitamin D Assay - Product Description 24
Table 24: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 25
Table 25: Nanotrap Human Growth Hormone Test - Product Status 25
Table 26: Nanotrap Human Growth Hormone Test - Product Description 25
Table 27: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 26
Table 28: Diagnostic Test - Menopause - Product Status 26
Table 29: Diagnostic Test - Menopause - Product Description 26
Table 30: DIANA Biotechnologies Pipeline Products & Ongoing Clinical Trials Overview 27
Table 31: DIANA Assay - Insulin-like Growth Factor Receptor - Product Status 27
Table 32: DIANA Assay - Insulin-like Growth Factor Receptor - Product Description 27
Table 33: DiaSorin SpA Pipeline Products & Ongoing Clinical Trials Overview 28
Table 34: LIAISON - High Sclerostin Assay - Product Status 28
Table 35: LIAISON - High Sclerostin Assay - Product Description 29
Table 36: LIAISON - Hyperphosphate Low Bone Turnover Assay - Product Status 29
Table 37: LIAISON - Hyperphosphate Low Bone Turnover Assay - Product Description 29
Table 38: LIAISON XL - Sclerostin Assay - Product Status 30
Table 39: LIAISON XL - Sclerostin Assay - Product Description 30
Table 40: Immunodiagnostic Systems Holdings plc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 41: IDS-iSYS Cortisol Assay - Product Status 31
Table 42: IDS-iSYS Cortisol Assay - Product Description 31
Table 43: IDS-iSYS MGP Assay - Product Status 32
Table 44: IDS-iSYS MGP Assay - Product Description 32
Table 45: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 33
Table 46: Rapid Diagnostic Test - Vitamin D - Product Status 33
Table 47: Rapid Diagnostic Test - Vitamin D - Product Description 33
Table 48: OJ-Bio Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 35
Table 49: Parathyroid Hormone Assay - Product Status 35
Table 50: Parathyroid Hormone Assay - Product Description 35
Table 51: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 36
Table 52: Cobas 6000 Analyzer Series With c 501 Module - IGF BP3 Assay - Product Status 36
Table 53: Cobas 6000 Analyzer Series With c 501 Module - IGF BP3 Assay - Product Description 37
Table 54: Cobas 6000 Analyzer Series With c 501 Module - IGF-1 Assay - Product Status 37
Table 55: Cobas 6000 Analyzer Series With c 501 Module - IGF-1 Assay - Product Description 37
Table 56: Cobas 8000 Analyzer Series With c 502 Module - IGF BP3 Assay - Product Status 37
Table 57: Cobas 8000 Analyzer Series With c 502 Module - IGF BP3 Assay - Product Description 38
Table 58: Cobas 8000 Analyzer Series With c 502 Module - IGF-1 Assay - Product Status 38
Table 59: Cobas 8000 Analyzer Series With c 502 Module - IGF-1 Assay - Product Description 38
Table 60: Cobas 8000 Analyzer Series With c 701 Module - IGF BP3 Assay - Product Status 40

List of Figures
Figure 1: Individual and Specified Hormones - Pipeline Products by Stage of Development 8
Figure 2: Individual and Specified Hormones - Pipeline Products by Segment 9
Figure 3: Individual and Specified Hormones - Pipeline Products by Territory 10
Figure 4: Individual and Specified Hormones - Pipeline Products by Regulatory Path 11
Figure 5: Individual and Specified Hormones - Pipeline Products by Estimated Approval Date 12

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Individual and Specified Hormones - Medical Devices Pipeline Assessment, 2019

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027